HER2 Support Group Forums - View Single Post - more on risks associated with G-CSF and GM-CSF which support White blood cells wchemo

Rich66 · 07-18-2009, 05:30 PM

1: Curr Opin Support Palliat Care. 2009 Jun 22. [Epub ahead of print] Links: Advances in the treatment of neutropenia.

Dale DC.
Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA.
PURPOSE OF REVIEW: The present review updates treatment of neutropenia from articles published from January 2008 through April 2009. RECENT FINDINGS: Chemotherapy-induced neutropenia occurs most commonly in the first cycle of treatment. Older patients, patients with multiple comorbidities, and those receiving more myelotoxic drugs are prone to develop neutropenia and its complications. Current guidelines recommend the prophylactic use of the myeloid growth factors for the first cycle of chemotherapy for patients with more than a 20% risk of febrile neutropenia. Meta analysis from randomized trials shows that granulocyte colony-stimulating factor prophylaxis is associated with patients receiving more intensive chemotherapy, having better survival, but also having a higher risk of secondary acute myeloid leukemia. Antibiotics are standard treatment of febrile neutropenia and are increasingly used for prophylaxis in 'low-risk' patients. SUMMARY: The myeloid growth factor granulocyte colony-stimulating factor has radically changed our approach to the prevention of febrile neutropenia. Antibiotics remain the mainstay of treatment of febrile neutropenia.

07-18-2009, 05:30 PM	#5
Rich66 Senior Member Join Date: Feb 2008 Location: South East Wisconsin Posts: 3,431	1: Curr Opin Support Palliat Care. 2009 Jun 22. [Epub ahead of print] Links Advances in the treatment of neutropenia. Dale DC. Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA. PURPOSE OF REVIEW: The present review updates treatment of neutropenia from articles published from January 2008 through April 2009. RECENT FINDINGS: Chemotherapy-induced neutropenia occurs most commonly in the first cycle of treatment. Older patients, patients with multiple comorbidities, and those receiving more myelotoxic drugs are prone to develop neutropenia and its complications. Current guidelines recommend the prophylactic use of the myeloid growth factors for the first cycle of chemotherapy for patients with more than a 20% risk of febrile neutropenia. Meta analysis from randomized trials shows that granulocyte colony-stimulating factor prophylaxis is associated with patients receiving more intensive chemotherapy, having better survival, but also having a higher risk of secondary acute myeloid leukemia. Antibiotics are standard treatment of febrile neutropenia and are increasingly used for prophylaxis in 'low-risk' patients. SUMMARY: The myeloid growth factor granulocyte colony-stimulating factor has radically changed our approach to the prevention of febrile neutropenia. Antibiotics remain the mainstay of treatment of febrile neutropenia.